Get the Stockscreener App
5.64
4.08%
-0.24
After Hours:
5.52
-0.12
-2.13%
Immunitybio Inc stock is traded at $5.64, with a volume of 18.02M.
It is down -4.08% in the last 24 hours and up +171.15% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$5.88
Open:
$5.72
24h Volume:
18.02M
Relative Volume:
0.74
Market Cap:
$5.56B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-5.8144
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
-4.57%
1M Performance:
+171.15%
6M Performance:
+134.02%
1Y Performance:
+76.80%
1-Day Range:
$5.58
$5.98
1-Week Range:
$5.58
$6.75
52-Week Range:
$1.83
$8.28
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
5.64 | 5.79B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.81 | 119.38B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.63 | 81.46B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
820.31 | 52.65B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.24 | 46.50B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.00 | 38.95B | 4.98B | 69.60M | 525.67M | 0.5198 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
ImmunityBio Accelerates Pipeline with New Lymphoma Trial Amid Stellar Revenue Forecast - AD HOC NEWS
Soon-Shiong, ImmunityBio Exit Challenge to Cancer Drug Financing - Bloomberg Law News
ImmunityBio Stockholder Targets Soon-Shiong In Chancery - Law360
ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.3%Should You Buy? - MarketBeat
Soon-Shiong Defends ImmunityBio Financing Pact for Cancer Drug - Bloomberg Law News
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Bath & Body Works, Inc. of Class Action Lawsuit and Upcoming Deadlines – BBWI - GlobeNewswire Inc.
IBRX garners retail attention on positive update in immunotherapy for lung cancer patients - MSN
ImmunityBio Shares Maintain Upward Momentum on Clinical and Commercial Progress - AD HOC NEWS
ImmunityBio Stock Maintains Momentum with New Clinical Trial - AD HOC NEWS
ImmunityBio (NASDAQ:IBRX) Trading Down 1.9%Should You Sell? - MarketBeat
Immunitybio Initiates Another Cell Therapy Trial With No Chemotherapy Needs - Stocktwits
Piper Sandler See Label Expansion Potential for ImmunityBio, Inc. (IBRX)’s ANKTIVA Following QUILT Data - Yahoo Finance
ImmunityBio Launches Phase 2 Study of Cell Therapy in Indolent Lymphomas - marketscreener.com
ImmunityBio launches phase 2 chemotherapy-free car-nk cell therapy trial with Anktiva - marketscreener.com
ImmunityBio launches phase 2 trial for chemotherapy-free lymphoma therapy - Investing.com
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas - Business Wire
ImmunityBio Stock: Commercialization Efforts Accelerate Following Key Approvals - AD HOC NEWS
ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock - TechStock²
ImmunityBio (IBRX) sheds 4% on profit-taking after 14-day run - MSN
Biotech Stocks To Keep An Eye OnJanuary 31st - MarketBeat
Why ImmunityBio Inc. (IBRX) Went Down On Tuesday? - MSN
Clinical Promise and Regulatory Scrutiny Collide for ImmunityBio - AD HOC NEWS
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
ImmunityBio Stock Surges on Clinical and Commercial Momentum - AD HOC NEWS
ImmunityBio stock rebounds: FDA scrutiny, a $505 million note and the next catalyst for IBRX - TechStock²
ImmunityBio (NASDAQ:IBRX) Trading Up 6.6%Here's Why - MarketBeat
ImmunityBio Stock Skyrockets Amid FDA Progress and Clinical Advances - StocksToTrade
MAHA Action Media Hub - ImmunityBio
Scrutiny Over FDA Communications Weighs on ImmunityBio Shares - AD HOC NEWS
IBRX stock gains pre-market after a volatile trading session following phase 2 glioblastoma trial update: Retail backs ImmunityBio’s cancer research - MSN
Lilly, Repertoire strike $2 billion autoimmune alliance - statnews.com
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc.IBRX - marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc.IBRX - PR Newswire
Brokers Offer Predictions for ImmunityBio FY2027 Earnings - MarketBeat
ImmunityBio’s Soon-Shiong mischaracterized talks with FDA over cancer drug, sources say - statnews.com
A High-Stakes Surge for ImmunityBio Shares - AD HOC NEWS
Positive Regulatory Developments and Stellar Growth for ImmunityBio - AD HOC NEWS
ImmunityBio Surges on Trial Success and Saudi FDA Approvals - timothysykes.com
ImmunityBio Stocks Surge Amid Clinical Advances and Strategic Growth - StocksToTrade
ImmunityBio (NASDAQ:IBRX) Shares Down 6%Should You Sell? - MarketBeat
Promising Biotech Stocks To ResearchJanuary 28th - MarketBeat
ImmunityBio (IBRX) Sheds 4% on Profit-Taking After 14-Day Run - Finviz
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment - Investing News Network
ImmunityBio Shares Pull Back Following Significant Advance - AD HOC NEWS
How Is The Market Feeling About ImmunityBio Inc? - Benzinga
Brokers Set Expectations for ImmunityBio FY2030 Earnings - MarketBeat
Is It Too Late To Reassess ImmunityBio (IBRX) After The Recent Oncology Headlines? - Yahoo Finance
ImmunityBio (NASDAQ:IBRX) Shares Gap DownHere's What Happened - MarketBeat
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer - AOL.com
ImmunityBio, Inc. (IBRX) Stock Analysis: Potential Upside Of 90% For This Biotech Innovator - DirectorsTalk Interviews
ImmunityBio Stock Surge Backed by Strong Fundamentals - AD HOC NEWS
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
2.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):